Companies sign distribution deal
DUBAI: G42 Healthcare, the Abu Dhabi-based health-tech company, announced the signing of a distribution agreement with Oxford Nanopore as a channel partner for their DNA/RNA sequencing products across Gulf Co-operation Council (GCC) countries, Jordan, Pakistan, Egypt, and Iraq.
This agreement is aligned with G42 Healthcare’s vision to make UAE the regional hub of health and life sciences by offering technology for real-time, accurate, accessible, and scalable analysis of DNA and RNA. The technology supports scientific analyses to further understand the biology of humans, bacteria, viruses, and environments as well as to understand diseases such as cancer.
With this channel partnership, G42 Healthcare aims to build on its current sequencing capabilities by offering Oxford Nanopore’s sequencing technology, which offers a range of market-disrupting features. This includes the ability to sequence any length of DNA/RNA fragments, from short to ultra-long, thereby offering richer genomic insights; the ability to stream data in real-time for rapid insights; the ability to sequence native DNA/RNA strands to elucidate richer information including real-time methylation data. A range of analyses from whole genome assembly to targeted sequencing or metagenomic analysis can be performed.
Talking about the distribution agreement with Oxford Nanopore, Ashish Koshy, CEO of G42 Healthcare, said: “G42 Healthcare has leveraged nanopore sequencing to facilitate the world’s most comprehensive population genomics initiative in the UAE, and therefore, has a deep understanding of how to deliver at scale, from sample management to advanced analytics. In line with this, our agreement with Oxford Nanopore assumes great significance as it will help us achieve real-time, high-performance, accessible, and scalable analysis of DNA and RNA, to support rapid clinical research and outbreak surveillance. We are excited about potential future developments that could include providing high-impact testing with nanopore sequencing.”